Open AccessClinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
Author(s) -
Ettienne J. Myburgh,
L Langenhoven,
Kathleen A. Grant,
Lize van der Merwe,
Maritha J. Kotze
Publication year - 2017
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2016.006072
Subject(s) - polysomy , subtyping , breast cancer , immunohistochemistry , fluorescence in situ hybridization , medicine , estrogen receptor , progesterone receptor , oncology , cancer , univariate analysis , hormone receptor , gynecology , pathology , biology , chromosome , gene , multivariate analysis , genetics , computer science , programming language
Human epidermal growth factor receptor 2 (HER2) positivity is an important prognostic and predictive indicator in breast cancer. HER2 status is determined by immunohistochemistry and fluorescent in situ hybridization (FISH), which are potentially inaccurate techniques as a result of several technical factors, polysomy of chromosome 17, and amplification or overexpression of CEP17 (centromeric probe for chromosome 17) and/or HER2. In South Africa, HER2-positive tumors are excluded from a MammaPrint (MP; Agendia BV, Amsterdam, Netherlands) pretest algorithm. Clinical HER2 status has been reported to correlate poorly with molecular subtype. The aim of this study was to investigate the correlation of clinical HER2 status with BluePrint (BP) molecular subtyping.